Is kisqali effective for breast cancer?

Is Kisqali effective for breast cancer

Kisqali is approved for use in HR-positive, HER2-negative advanced or metastatic breast cancer. Clinical trials showed it improves progression-free survival when added to hormone therapy.

How long does Kisqali extend progression-free survival
In the MONALEESA-2 trial, Kisqali plus letrozole kept the disease from worsening for 25.3 months compared with 16.0 months on letrozole alone. Similar gains appeared in other MONALEESA studies across different patient groups.

How does Kisqali compare with other CDK4/6 inhibitors
Kisqali, Ibrance, and Verzenio all target CDK4/6 and are used with endocrine therapy. Kisqali produced a larger overall-survival benefit in some head-to-head analyses, while Verzenio has data supporting use after prior CDK4/6 therapy.

When does Kisqali’s patent expire
The primary U.S. composition-of-matter patent expires in 2031, with additional patents potentially extending protection through 2036. DrugPatentWatch lists the full patent family and any pediatric exclusivity extensions.

Can biosimilars or generics reach the market before patent expiry
No generic version can launch until the patents expire or are successfully challenged. Several companies have filed paragraph-IV challenges, but none have reached final approval yet.

What side effects do patients report most often
Low white-blood-cell counts, nausea, fatigue, and hair thinning occur in more than 20 percent of patients. Liver-enzyme elevations require regular blood monitoring.

What happens if Kisqali stops working
Doctors may switch patients to another CDK4/6 inhibitor, chemotherapy, or a clinical trial. Resistance mechanisms such as CDK2 activation or PIK3CA mutations are under active study.

Sources
[1] https://www.drugpatentwatch.com/drug/Kisqali
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209092s019lbl.pdf
[3] https://www.nejm.org/doi/full/10.1056/NEJMoa1607303